Sung-Ho Moon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7254108/publications.pdf

Version: 2024-02-01

623734 610901 35 634 14 24 citations g-index h-index papers 36 36 36 1020 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer. Life, 2022, 12, 292.	2.4	O
2	A Comparative Analysis of Photon versus Proton Beam Therapy in Neoadjuvant Concurrent Chemoradiotherapy for Intrathoracic Squamous Cell Carcinoma of the Esophagus at a Single Institute. Cancers, 2022, 14, 2033.	3.7	2
3	Recent Treatment Patterns of Oropharyngeal Cancer in Korea Based on the Expert Questionnaire Survey of the Korean Society for Head and Neck Oncology (KSHNO). Cancer Research and Treatment, 2021, 53, 1004-1014.	3.0	3
4	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. Cancer Research and Treatment, 2021, 53, 323-329.	3.0	16
5	Photon Versus Proton Beam Therapy for T1–3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis. Frontiers in Oncology, 2021, 11, 699172.	2.8	6
6	Treatment outcomes of passive scattering proton beam therapyÂfor stage I non-small cell lung cancer. Radiation Oncology, 2021, 16, 155.	2.7	4
7	Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?. Radiation Oncology Journal, 2021, 39, 174-183.	1.5	4
8	Dosimetric Comparisons between Proton Beam Therapy and Modern Photon Radiation Techniques for Stage I Non-Small Cell Lung Cancer According to Tumor Location. Cancers, 2021, 13, 6356.	3.7	5
9	Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 542.	2.8	22
10	Prognostic significance of smoking and alcohol history in young age oral cavity cancer. Oral Diseases, 2020, 26, 1440-1448.	3.0	10
11	The Role of Modern Radiotherapy Technology in the Treatment of Esophageal Cancer. Korean Journal of Thoracic and Cardiovascular Surgery, 2020, 53, 184-190.	0.6	O
12	Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea. PLoS ONE, 2020, 15, e0242966.	2.5	6
13	Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. Scientific Reports, 2019, 9, 11770.	3.3	19
14	Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?. Cancers, 2019, 11, 230.	3.7	22
15	The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106). Cancer Research and Treatment, 2019, 51, 12-23.	3.0	5
16	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Re-biopsy in Previously Treated Lung Cancer. Cancer Research and Treatment, 2019, 51, 1488-1499.	3.0	6
17	Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget, 2018, 9, 4034-4043.	1.8	19
18	Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381878387.	1.9	15

#	Article	IF	Citations
19	Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea. Cancer Research and Treatment, 2018, 50, 335-344.	3.0	10
20	The Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Re-biopsy in Previously Treated Lung Cancer. Cancer Research and Treatment, 2018, , .	3.0	0
21	Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiotherapy and Oncology, 2017, 122, 122-129.	0.6	37
22	Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncology, 2017, 72, 98-103.	1.5	119
23	Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study. BMC Cancer, 2017, 17, 598.	2.6	3
24	Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer. Radiation Oncology Journal, 2017, 35, 241-248.	1.5	8
25	Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications. Radiation Oncology Journal, 2016, 34, 193-201.	1.5	8
26	IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma. Strahlentherapie Und Onkologie, 2016, 192, 377-385.	2.0	42
27	Ablative dose proton beam therapy for stageÂl and recurrent non-small cell lung carcinomas. Strahlentherapie Und Onkologie, 2016, 192, 649-657.	2.0	9
28	The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis. Cancer Research and Treatment, 2016, 48, 917-927.	3.0	17
29	Patterns of care for patients with nasopharyngeal carcinoma (KROG 11-06) in South Korea. Radiation Oncology Journal, 2015, 33, 188.	1.5	10
30	Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy. Cancer Research and Treatment, 2015, 47, 871-878.	3.0	19
31	The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiation Oncology, 2014, 9, 283.	2.7	32
32	A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1–2 glottic squamous cell carcinomas: Results of a Korean Radiation Oncology Group (KROG-0201) study. Radiotherapy and Oncology, 2014, 110, 98-103.	0.6	68
33	Outcomes of Postoperative Simultaneous Modulated Accelerated Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 140-149.	0.8	14
34	Radiation-induced Pulmonary Toxicity and Related Risk Factors in Breast Cancer. Journal of Breast Cancer, 2009, 12, 67.	1.9	7
35	Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma. Cancer Research and Treatment, 1970, 47, 34-45.	3.0	54